{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:54:06Z","timestamp":1792403646339,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.<\/jats:p>","DOI":"10.1093\/ofid\/ofae070","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T14:10:16Z","timestamp":1707315016000},"source":"Crossref","is-referenced-by-count":11,"title":["Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-5937","authenticated-orcid":false,"given":"Amber C","family":"Streifel","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke C","family":"Strnad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University , Portland, Oregon , USA"},{"name":"School of Public Health, Epidemiology Programs, Oregon Health & Science University and Portland State University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica K","family":"Sikka","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara D","family":"Varley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University , Portland, Oregon , USA"},{"name":"School of Public Health, Epidemiology Programs, Oregon Health & Science University and Portland State University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Makadia","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Sukerman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyse H","family":"Douglass","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"James S","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"2024032722020174000_ofae070-B1","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024032722020174000_ofae070-B2","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024032722020174000_ofae070-B3","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024032722020174000_ofae070-B4","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1093\/cid\/ciaa008","article-title":"Bacterial infections associated with substance use disorders, large cohort of United States hospitals, 2012\u20132017","volume":"71","author":"McCarthy","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024032722020174000_ofae070-B5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/jac\/dkv344","article-title":"Vascular access complications during outpatient parenteral antimicrobial therapy at home: a retrospective cohort study","volume":"71","author":"Shrestha","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2024032722020174000_ofae070-B6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/cid\/ciw098","article-title":"Optimal duration of antibiotic therapy in patients with hematogenous vertebral osteomyelitis at low risk and high risk of recurrence","volume":"62","author":"Park","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024032722020174000_ofae070-B7","doi-asserted-by":"crossref","first-page":"e02280-18","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024032722020174000_ofae070-B8","doi-asserted-by":"crossref","first-page":"ofab589","DOI":"10.1093\/ofid\/ofab589","article-title":"Effectiveness of dalbavancin compared with standard of care for the treatment of osteomyelitis: a real-world analysis","volume":"9","author":"Cain","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024032722020174000_ofae070-B9"},{"key":"2024032722020174000_ofae070-B10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/1120009X.2021.2015649","article-title":"Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review","volume":"34","author":"Ramadan","year":"2022","journal-title":"J Chemother"},{"key":"2024032722020174000_ofae070-B11","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.12659\/AJCR.905930","article-title":"Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant staphylococcus aureus: a case report","volume":"18","author":"Almangour","year":"2017","journal-title":"Am J Case Rep"},{"key":"2024032722020174000_ofae070-B12","article-title":"The hidden cost of dalbavancin: OPAT RN time required in coordination for persons who use drugs","volume":"10","author":"Douglass","year":"2023","journal-title":"Ther Adv Infect Dis"},{"key":"2024032722020174000_ofae070-B13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"New Engl J Med"},{"key":"2024032722020174000_ofae070-B14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijantimicag.2019.08.007","article-title":"Dalbavancin use in an academic medical centre and associated cost savings","volume":"54","author":"Streifel","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2024032722020174000_ofae070-B15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"key":"2024032722020174000_ofae070-B16","doi-asserted-by":"crossref","first-page":"ofaa293","DOI":"10.1093\/ofid\/ofaa293","article-title":"Use of a standardized dalbavancin approach to facilitate earlier hospital discharge for vulnerable patients receiving prolonged inpatient antibiotic therapy","volume":"7","author":"Vazquez Deida","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024032722020174000_ofae070-B17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","article-title":"Strategies used by people who inject drugs to avoid stigma in healthcare settings","volume":"198","author":"Biancarelli","year":"2019","journal-title":"Drug Alcohol Dependence"},{"key":"2024032722020174000_ofae070-B18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11606-020-06201-6","article-title":"\u201cHealth is on the back burner.\u201d Multilevel barriers and facilitators to primary care among people who inject drugs","volume":"36","author":"Motavalli","year":"2021","journal-title":"J Gen Intern Med"},{"key":"2024032722020174000_ofae070-B19","doi-asserted-by":"crossref","first-page":"ofy132","DOI":"10.1093\/ofid\/ofy132","article-title":"Infectious diseases physicians\u2019 perspectives regarding injection drug use and related infections, United States, 2017","volume":"5","author":"Rapoport","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2024032722020174000_ofae070-B20","doi-asserted-by":"crossref","first-page":"S494","DOI":"10.1093\/infdis\/jiaa025","article-title":"Feasibility and safety of outpatient parenteral antimicrobial therapy in conjunction with addiction treatment for people who inject drugs","volume":"222","author":"Price","year":"2020","journal-title":"J Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae070\/56614017\/ofae070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/3\/ofae070\/57090555\/ofae070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/3\/ofae070\/57090555\/ofae070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T18:02:27Z","timestamp":1711562547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae070\/7602876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae070","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,2,7]]},"article-number":"ofae070"}}